カテゴリ： GlobalData, アメリカ, 企業調査

CEL-SCI Corp (CVM)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：CEL-SCI Corp (CVM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9963
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：72
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
CEL-SCI Corp (CEL-SCI) is a biotechnology company that carries out the research and development of new immunotherapy products for the treatment of various cancer and infectious diseases. Its core capabilities include drug discovery, research, development and manufacturing of compound biological substances. CEL-SCI’s lead candidate Multikine (leukocyte interleukin), is an investigational immunotherapy against cancer and human papilloma virus (HPV). The company is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 in hospitalized patients and vaccines CEL-2000 and CEL-4000 for rheumatoid arthritis using its Ligand Epitope Antigen Presentation System (LEAPS) technology platform. CEL-SCI is headquartered in Vienna, Virginia, the US.

CEL-SCI Corp (CVM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CEL-SCI Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine In HIV/HPV Co-Infected Patients With Peri-Anal Warts 12
Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine 13
Cel-Sci Expands Co-Development Agreement with Ergomed 14
Equity Offering 15
CEL-SCI Plans to Raise up to USD100 Million in Public Offering of Shares 15
CEL-SCI Raises USD5 Million in Private Placement of Shares 16
CEL-SCI Raises USD2.1 Million in Private Placement of shares up on Exercise of Warrants 17
CEL-SCI Files Registration Statement to Raise up to USD11 Million in Private Placement of Shares 18
CEL-SCI to Raise up to USD2.5 Million in Public Offering of Shares 19
CEL-SCI Raises USD2.4 Million in Private Placement of Shares and Warrants 20
CEL-SCI to Raise USD3.5 Million in Private Placement of Shares and Warrants 21
CEL-SCI to Raise USD2 Million in Private Placement of Shares upon Exercise of Warrants 22
CEL-SCI Raises USD1.5 Million in Private Placement of Shares and Warrants 23
CEL-SCI Raises USD1 Million in Private Placement of Shares and Warrants 25
CEL-SCI Raises USD4.3 Million in Public Offering of Shares 26
CEL-SCI Raises USD5 Million in Private Placement of Shares and Warrants 28
CEL-SCI Raises USD5 Million in Registered Direct Offering 29
CEL-SCI Raises USD0.6 Million in Priavte Palcement of Shares 30
CEL-SCI Raises USD1.1 Million in Private placement of Shares 31
Cel-Sci Raises USD11.5 Million in Public Offering of Shares and Warrants 32
Cel-Sci Raises USD16 Million in Public Offering of Shares and Warrants 34
CEL-SCI Raises USD16 Million in Public Offering of Shares and Warrants 35
Cel-Sci Raises USD6 Million in Public Offering of Shares and Warrants 36
Cel-Sci Raises USD3 Million upon Exercise of Warrants 38
Cel-Sci Completes Public Offering Of Units For US$10 Million 39
Cel-Sci Completes Public Offering Of Units For US$3.3 Million 40
Cel-Sci Completes Public Offering Of Units For US$17.8 Million 42
Cel-Sci Completes Public Offering Of Common Stock For US$11 Million 44
Cel-Sci Files Registration Statement For Public Offering Of Securities For US$50 Million 45
Cel-Sci Completes Private Placement Of Common Stock For US$6 Million 46
CEL-SCI Completes Private Placement Of Common Stock For US$5.8 Million 47
Debt Offering 48
CEL-SCI Raises USD1.2 Million in Private Placement of 4% Notes Due 2017 48
CEL-SCI Raises USD1.5 Million in Private Placement of 4% Notes Due 2017 49
CEL-SCI Corp – Key Competitors 50
CEL-SCI Corp – Key Employees 51
CEL-SCI Corp – Locations And Subsidiaries 52
Head Office 52
Recent Developments 53
Financial Announcements 53
Aug 14, 2018: CEL-SCI reports third quarter fiscal year 2018 financial results 53
May 15, 2018: CEL-SCI Announces Second Quarter Fiscal 2018 Financial Results 54
Feb 12, 2018: CEL-SCI Reports First Quarter Fiscal 2018 Financial Results 55
Dec 29, 2017: CEL-SCI Reports Fiscal 2017 Financial Results and Clinical & Corporate Developments 56
Aug 09, 2017: CEL-SCI Reports Third Quarter Fiscal Year 2017 Financial Results 57
May 10, 2017: CEL-SCI Reports Second Quarter Fiscal Year 2017 Financial Results 58
Feb 09, 2017: CEL-SCI Reports First Quarter Fiscal 2017 Financial Results 59
Corporate Communications 60
Aug 17, 2018: CEL-SCI Announces that the NYSE American approves plan 60
Dec 18, 2017: CEL-SCI Announces Robert Watson Joins its Board of Directors 61
Feb 27, 2017: CEL-SCI Announces That the NYSE MKT Approves Plan 62
Government and Public Interest 63
Sep 19, 2017: CEL-SCI Announces $1.5 Million NIH SBIR Grant to Support Development of Rheumatoid Arthritis Vaccine 63
Product News 64
05/16/2017: CEL-SCI Scientist Presents Data on CEL-4000 at AAI – IMMUNOLOGY 2017 Meeting 64
04/12/2017: CEL-SCI Scientist Presents at the World Vaccine Congress 65
02/21/2017: CEL-SCI Scientist Presents New Findings for Rheumatoid Arthritis Treatment Vaccine at Conference 66
Clinical Trials 67
Jun 08, 2017: CEL-SCI Announces New Data for Its Rheumatoid Arthritis Vaccine Candidate Published in Peer Reviewed Journal 67
Other Significant Developments 68
Jun 11, 2018: CEL-SCI Issues Letter to Shareholders 68
Apr 04, 2018: CEL-SCI: Letter to Shareholders 69
Jan 03, 2018: CEL-SCI Releases Letter to Shareholders 70
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72

List of Tables
CEL-SCI Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CEL-SCI Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CEL-SCI Corp, Deals By Therapy Area, 2012 to YTD 2018 9
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine In HIV/HPV Co-Infected Patients With Peri-Anal Warts 12
Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine 13
Cel-Sci Expands Co-Development Agreement with Ergomed 14
CEL-SCI Plans to Raise up to USD100 Million in Public Offering of Shares 15
CEL-SCI Raises USD5 Million in Private Placement of Shares 16
CEL-SCI Raises USD2.1 Million in Private Placement of shares up on Exercise of Warrants 17
CEL-SCI Files Registration Statement to Raise up to USD11 Million in Private Placement of Shares 18
CEL-SCI to Raise up to USD2.5 Million in Public Offering of Shares 19
CEL-SCI Raises USD2.4 Million in Private Placement of Shares and Warrants 20
CEL-SCI to Raise USD3.5 Million in Private Placement of Shares and Warrants 21
CEL-SCI to Raise USD2 Million in Private Placement of Shares upon Exercise of Warrants 22
CEL-SCI Raises USD1.5 Million in Private Placement of Shares and Warrants 23
CEL-SCI Raises USD1 Million in Private Placement of Shares and Warrants 25
CEL-SCI Raises USD4.3 Million in Public Offering of Shares 26
CEL-SCI Raises USD5 Million in Private Placement of Shares and Warrants 28
CEL-SCI Raises USD5 Million in Registered Direct Offering 29
CEL-SCI Raises USD0.6 Million in Priavte Palcement of Shares 30
CEL-SCI Raises USD1.1 Million in Private placement of Shares 31
Cel-Sci Raises USD11.5 Million in Public Offering of Shares and Warrants 32
Cel-Sci Raises USD16 Million in Public Offering of Shares and Warrants 34
CEL-SCI Raises USD16 Million in Public Offering of Shares and Warrants 35
Cel-Sci Raises USD6 Million in Public Offering of Shares and Warrants 36
Cel-Sci Raises USD3 Million upon Exercise of Warrants 38
Cel-Sci Completes Public Offering Of Units For US$10 Million 39
Cel-Sci Completes Public Offering Of Units For US$3.3 Million 40
Cel-Sci Completes Public Offering Of Units For US$17.8 Million 42
Cel-Sci Completes Public Offering Of Common Stock For US$11 Million 44
Cel-Sci Files Registration Statement For Public Offering Of Securities For US$50 Million 45
Cel-Sci Completes Private Placement Of Common Stock For US$6 Million 46
CEL-SCI Completes Private Placement Of Common Stock For US$5.8 Million 47
CEL-SCI Raises USD1.2 Million in Private Placement of 4% Notes Due 2017 48
CEL-SCI Raises USD1.5 Million in Private Placement of 4% Notes Due 2017 49
CEL-SCI Corp, Key Competitors 50
CEL-SCI Corp, Key Employees 51

List of Figures
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[CEL-SCI Corp (CVM)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • SK Bioland Co Ltd：企業の戦略・SWOT・財務情報
    SK Bioland Co Ltd - Strategy, SWOT and Corporate Finance Report Summary SK Bioland Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • NanoString Technologies Inc (NSTG)：製薬・医療：M&Aディール及び事業提携情報
    Summary NanoString Technologies Inc (NanoString) is a developer of life science tools for translational research and molecular diagnostics. The company's products include sprint profiler, Dx analysis system with flex, nCounter MAX analysis system, protein assays, solid tumor assays, gene fusion pane …
  • Event Hospitality & Entertainment Ltd：企業の戦略・SWOT・財務情報
    Event Hospitality & Entertainment Ltd - Strategy, SWOT and Corporate Finance Report Summary Event Hospitality & Entertainment Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Ultragenyx Pharmaceutical Inc (RARE)：企業の財務・戦略的SWOT分析
    Ultragenyx Pharmaceutical Inc (RARE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • GAIL (India) Ltd (GAIL)
    GAIL (India) Ltd (GAIL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Lyka Labs Ltd (LYKALABS)-製薬・医療分野：企業M&A・提携分析
    Summary Lyka Labs Ltd (Lyka Labs) is a developer and manufacturer of pharmaceutical formulations and active pharmaceutical ingredients. The company offers development of various formulations which include lyophilized injections, differentiated dermatological formulation, dry powder injections, and o …
  • PT Pudjiadi Prestige Tbk：企業の戦略・SWOT・財務情報
    PT Pudjiadi Prestige Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Pudjiadi Prestige Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Bank Of Ningbo Co. Ltd.
    Bank Of Ningbo Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Bank Of Ningbo Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • NorgesGruppen ASA：企業の戦略的SWOT分析
    NorgesGruppen ASA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Magnetek Inc：企業の戦略的SWOT分析
    Magnetek Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Consolidated Edison Company of New York Inc：電力：M&Aディール及び事業提携情報
    Summary Consolidated Edison Company of New York, Inc. (CECONY), a subsidiary of Consolidated Edison, Inc. is an energy utility that generates, transmits and distributes electricity; supplies natural gas; and generates and supplies steam. The company provides electricity and related services in New Y …
  • Theralase Technologies Inc (TLT)：製品パイプライン分析
    Summary Theralase Technologies Inc (Theralase) is a medical equipment company that designs, develops and manufactures laser and laser technology for human, companion animal and equine applications. The company offers products such as controller, multiple probe, triple probe, single probe, multiple p …
  • Ralph Lauren Corp：企業の戦略・SWOT・財務分析
    Ralph Lauren Corp - Strategy, SWOT and Corporate Finance Report Summary Ralph Lauren Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Chubb Limited：企業の戦略・SWOT・財務情報
    Chubb Limited - Strategy, SWOT and Corporate Finance Report Summary Chubb Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Credit Suisse Group AG：企業のM&A・事業提携・投資動向
    Credit Suisse Group AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Credit Suisse Group AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Oxeia Biopharmaceuticals Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Oxeia Biopharmaceuticals Inc (Oxeia Biopharmaceuticals) is a clinical stage biotech company that develops drug treatments for mild traumatic brain injury or concussion and underlying neuro-metabolic dysfunction. The company’s lead pipeline candidate includes OXE-103, potent mitochondrial sta …
  • Endotronix Inc：医療機器：M&Aディール及び事業提携情報
    Summary Endotronix Inc (Endotronix) is a medical technology company that offers digital health solutions. The company offers Cordella Heart Failure System with an implantable wireless pulmonary artery sensor for early detection of worsening heart failure. Endotronix’s solution includes an implanted …
  • APR Applied Pharma Research SA-製薬・医療分野：企業M&A・提携分析
    Summary APR Applied Pharma Research SA (APR) is a healthcare company which focuses on the development and licenses of healthcare products for rare therapeutic areas. The company offers consumer health products, prescription healthcare products and therapeutic products. APR’s product pipeline portfol …
  • Empresa Nacional del Petroleo：企業の戦略的SWOT分析
    Empresa Nacional del Petroleo - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Bank Of Panhsin：企業の戦略・SWOT・財務分析
    Bank Of Panhsin - Strategy, SWOT and Corporate Finance Report Summary Bank Of Panhsin - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆